Concord Medical Services

Concord Medical Services Holdings Ltd. engages in the operation of radiotherapy and diagnostic imaging centers. It provides radiotherapy and diagnostic equipment leasing services to hospitals; and sale of medical equipment and the provision of radiotherapy and diagnostic equipment leasing and management services to hospitals, It operates through Network Business and Hospital Business segments. The company was founded on November 27, 2007 and is headquartered in Beijing, China.

Concord Medical Services Holdings Ltd. engages in the provision of operation of radiotherapy and diagnostic imaging centers. It operates through Network Business and Hospital Business segments. It provides radiotherapy and diagnostic equipment leasing services to hospitals, and sale of medical equipment and the provision of radiotherapy and diagnostic equipment leasing and management services to hospitals. The company was founded on November 27, 2007 and is headquartered in Beijing, China.

VANCOUVER, British Columbia--( BUSINESS WIRE )--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (“Canagold” or “the Company”) is pleased to announce its high-grade gold assay results for 21 drill holes from the recently completed 9,000-metre drill program which has confirmed the high-grade and near-surface gold potential of the Y-Vein System at New Polaris.

Canagold Confirms Near Surface High-Grade Gold, Including 53.8 gpt Au over 2.78 m and 18.0 gpt Au over 5.64 m in Y-Vein System at New Polaris

VANCOUVER, British Columbia--( BUSINESS WIRE )--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce it has signed an agreement with the Taku River Tlingit First Nation (“TRTFN”) in respect of development of the Company's New Polaris project (“New Polaris”, or the “project”) located within the traditional territory of the TRTFN located approximately 100 kilometres south of Atlin, B.C.

Canagold Announces Agreement with Taku River Tlingit First Nation for Flagship New Polaris Project

VANCOUVER, British Columbia--( BUSINESS WIRE )--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce the Company has closed its previously announced rights offering which expired on December 9, 2022 (the “Rights Offering”). At closing, Canagold issued 25,277,221 common shares of the Company (the “Shares”) to rightsholders at a price of $0.175 per Share for total gross proceeds of $4,423,514 and an additional 20,352,577 Shares to Sun Valley Investments AG (“Sun Valley”) pursuant to Canagold's Rights Offering Standby Guaranty Agreement, dated October 28, 2022 with Sun Valley.

Canagold Announces Closing of Fully Subscribed Rights Offering

BEIJING , Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2022 annual general meeting of shareholders (the "Meeting") on December 30, 2022, at 10:00 a.m. (Beijing Time).

Concord Medical Schedules 2022 Annual Meeting of Shareholders

BEIJING , Nov. 16, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced the successful holding of the Second Annual Academic Meeting (the "Meeting") jointly by Shanghai Concord Cancer Center and The University of Texas MD Anderson Cancer Center ("MD Anderson") on November 11 and November 12, 2022. With the theme of "Immuno-Oncology: Confronting the Whole Cancer Continuum," the Meeting gathered a number of well-known oncologists and scholars from China and the United States to share their cutting-edge academic achievements in various ways, to promote academic communications and cooperation in oncology worldwide.

Concord Medical Announces the Successful Holding of the Second Annual Academic Meeting with the world well-known MD Anderson

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd.

Canagold Announces Filing of a Rights Offering Circular

Canagold Announces Launch of Guaranteed Rights Offering

VANCOUVER--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd.

Canagold Drills 22.1 Grams Per Tonne Gold Over 4.3 Metres in Y-Vein System at New Polaris

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce it has retained Ausenco Engineering Canada Inc. (“Ausenco”) to complete a feasibility study on the Company's New Polaris project (“New Polaris”, or the “project”) located in Northwestern B.C. “I'm delighted to announce Canagold's selection of Ausenco to undertake the feasibility study at New Polaris,” said Catalin Kilofliski, CEO

Canagold Retains Ausenco Engineering to Complete Feasibility Study on New Polaris Project

BEIJING , Sept. 30, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced changes in its management.

Concord Medical Announces Changes in Management

BEIJING , Sept. 23, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2022[1].

Concord Medical Reports Financial Results for the First Half of 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), wishes to confirm that to ensure the Company remains well funded for the duration of its upcoming feasibility study, permitting and drilling at the New Polaris project, additional financing plans are under consideration. Canagold is currently evaluating various financing options to secure additional sources of capital, including private placement, a rig

Canagold Resources Announces Additional Financing Plans

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce it has arranged up to $4 million in debt and equity financing to fund the Company's drilling activities for the remainder of 2022. Specifically, Canagold has arranged a $1.5M charity flow-through financing (the “Charity FT”) that will be priced at a premium to the current market price and determined in the context of the market up

Canagold Resources Arranges $4M Financing

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce the issue of its request for tender to seven qualified consulting engineering firms to complete a feasibility study for the New Polaris project in Northwestern BC. A Preliminary Economic Assessment (PEA) conducted by Moose Mountain Technical Services in February 2019 demonstrated the robust economic viability of the project. Using

Canagold Resources Tenders Proposals for New Polaris Feasibility Study

BEIJING , June 1, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that its subsidiary, Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a company incorporated in China, filed an application (the "Application") to list a minority stake of its shares (the "Concord Healthcare  Shares") on The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") (the "Listing") on May 31, 2022.

Concord Medical Announces Its Subsidiary's Application Filing for Potential Listing on The Stock Exchange of Hong Kong Limited

BEIJING , April 29, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.

Concord Medical Files 2021 Annual Report on Form 20-F

BEIJING, Dec. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research, and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2021 [1]. 2021 First Half Highlights Total net revenues were RMB192.9 million ($29.9 million) in the first half of 2021, representing a 132.4% increase from total net revenues of RMB83.0 million in the same period last year.

Concord Medical Reports Financial Results for the First Half of 2021

BEIJING, Nov. 29, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2021 annual general meeting of shareholders (the "Meeting") on December 29, 2021, at 10:00 a.m. (Beijing Time).

Concord Medical Schedules 2020 Annual Meeting of Shareholders

BEIJING, Oct. 21, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that its Guangzhou Concord Cancer Center ("GCCC"), has obtained the qualifications of Social Healthcare Insurance designated medical institution, allowing more patients to gain access to high quality medical services with a lower self-paying proportion. Supported by National Healthcare Security Administration, the Social Healthcare Insurance system is the most important player in the healthcare industry which covers over 95% of China's population (approximately 13.5 billion).

Guangzhou Concord Cancer Center Becomes a Designated Hospital of Social Healthcare Insurance

BEIJING, Oct. 18, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that two projects of it, Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform ("Jiahe Cloud") and Jiahe Feiyun Intelligent Radiotherapy Cloud Service Platform ("Jiahe Feiyun"), were successfully shortlisted by the "5G+Healthcare" pilot project, which is launched by Ministry of Industry and Information Technology. Jiahe Cloud provides digitized solutions, with remote diagnosis as the core service, for medical institutions.

Concord Medical Is Shortlisted for the "5G+Healthcare" Pilot Project

BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers, premium cancer hospitals, and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at  http://ir.ccm.cn  and on the SEC's website at  www.sec.gov.

Concord Medical Files 2020 Annual Report on Form 20-F

BEIJING, Sept. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that Shanghai Concord Cancer Center ("SCCC", or the "planned hospital"), a business subsidiary of an important operating platform of the Company, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd.

Concord Medical Purchases Additional Proton Therapy System for It's Shanghai Concord Cancer Center

BEIJING, Aug. 23, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializes in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced an investment of RMB400.0 million (US$62.2 million) in Concord Medical's subsidiary, Meizhong Jiahe Medical Science & Technology Development Group Co., Ltd. ("Meizhong Jiahe") from several investors led by WisdoMont Asset Management (Shanghai) Co., Ltd.

Concord Medical Completes RMB 400 Million Funding Round Led by Consortium Investors

BEIJING, June 11, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that its Guangzhou Concord Cancer Center ("GCCC"), which is certified as a tertiary specialty hospital by the National Health Commission, is now in operation. This has marked a major milestone for the Company.

Concord Medical Officially Opens New Specialty Cancer Hospital in Guangzhou

BEIJING, May 25, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that as of May 25, 2021, it is late in filing its annual report on Form 20-F for the fiscal year ended December 31, 2020 (the "2020 Annual Report") with the Securities and Exchange Commission (the "SEC").  The Company previously filed a Form 12b-25 with the SEC on April 30, 2021 for late filing of the 2020 Annual Report, pursuant to which the 2020 Annual Report was due to be filed by May 17, 2021.

News for Concord Medical Services Stock (CCM)